Xpert® MTB/RIF
Accurate Detection of MTB and Rifampin Resistance Mutations
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXMTB/RIF-US-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Each day, more than 3,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
  • In the United States, 22% of people affected by TB are still not diagnosed by the WHO-recommended rapid diagnostic test1
  • Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
1 Global Tuberculosis Report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023. Accessed Jan 2024.
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB-- https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm. Accessed Jan 2024.

The Solution

The Xpert MTB/RIF test provides fast and accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
  • Simple three-step process with results in less than 2 hours
  • Designed to provide the most accurate MTB and Rifampicin detection
  • On-demand capability that empowers physicians to manage patients effectively

The Impact

  • Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes3
  • Significantly reduces AII (airborne infection isolation) duration compared to the smear microscopy3
  • Implementation is highly cost-effective for diagnosing pulmonary TB in the United States4
3 Christopher K. Lippincott et al, Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States Clin Infect Dis. 2014 Jul 15; 59(2): 186–19

4 H. W. Choi, et al, Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States Int J Tuberc Lung Dis. 2013 October ; 17(10): 1328–1335